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E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, 
whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated 
E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive 
breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and 
case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. 
Survival analyses were performed using Cox regression models. All analyses were stratified by 
estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more 
frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression 
(score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared 
to never users, OR = 1.24, 95% CI = 0.97–1.59), which was stronger when we evaluated complete loss 
of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06–2.33. Breast cancer specific mortality was 
unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated 
with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an 
association with breast cancer specific survival. These data support loss of E-cadherin expression as an 
important marker of tumor subtypes.
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The E-cadherin protein (encoded by the CDH1 gene) is normally expressed in breast epithelial tissue and func-
tions as a critical part of epithelial cell adhesion and epithelial-to-mesenchymal transition (EMT)1–3. Due to the 
frequent loss or inactivation of E-cadherin that is evident in epithelial cell cancers, E-cadherin is thought to have 
tumor-suppressor properties where loss is associated with carcinogenesis and invasion4,5.
Loss of E-cadherin expression is commonly used to confirm lobular histology that comprise 10–15% of all 
breast cancers6–8, which have also been noted to more frequently express hormone receptors [estrogen recep-
tor (ER) and progesterone receptor (PR)] than E-cadherin high tumors9. Recent molecular profiling analysis 
of lobular compared with ductal cancers show E-cadherin mutation and loss to be a defining feature of lobular 
breast cancers, and suggest it to be a distinct molecular subtype of breast cancers10. Although many studies have 
identified heterogeneity in risk factor associations based on breast tumor subtypes defined by hormone receptor 
status (e.g. ER-positive vs. ER-negative) or histology (lobular vs. ductal)11–22, limited data have examined whether 
E-cadherin may define important subgroups of tumors with distinct etiologies23.
Data also suggest that loss of E-cadherin expression may be associated with malignant progression, metastasis, 
and reduced survival in breast cancer patients24–28; however, most of these studies were based on small numbers 
and not all analyses were stratified by ER-status, a known important prognostic and predictive marker.
Evidence on whether E-cadherin may be an important marker of etiologic heterogeneity and survival differ-
ences across the spectrum of breast tumor subtypes including ER status and histology is limited. In 1984, Prentice 
et al.29 introduced the concept of using case-case studies for identifying disease risk factors. In a case-case study 
design, information is obtained only from cases of a particular disease–in our study, breast cancer–and is used 
as a tool to assess etiologic heterogeneity. In this study, we were interested in determining whether known risk/
protective factors for breast cancer differed by E-cadherin expression, in order to provide new insights into pos-
sible mechanisms for E-cadherin loss in breast carcinogenesis similar to analyses previously done for ER, PR and 
HER2 markers23,30,31. Using immunohistochemical (IHC) data for E-cadherin performed centrally using tumor 
tissue microarrays (TMAs), we performed a large pooled analysis of 12 studies participating in the Breast Cancer 
Association Consortium (BCAC), and examined whether established breast cancer risk factor associations and 
survival differed by low vs. high E-cadherin tumor tissue expression, stratified by ER status and histology.
Material and Methods
Study Population. Descriptions of the 12 breast cancer studies participating in the Breast Cancer 
Association Consortium (BCAC) included in this analysis are detailed in Supplemental Table 1. Case-case anal-
yses were restricted to 5,933 European women from 12 breast cancer studies with invasive breast cancer who 
provided data on age at diagnosis and had evaluable E-cadherin tumor tissue staining results (See section on 
E-cadherin tumour tissue measurements). Study participants were recruited under protocols approved by the 
and Global health, The University of Melbourne, Melbourne, Victoria, Australia. 10Department of Pathology, 
Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz IdiPAZ, and Facultad de Medicina, 
Universidad Autonoma de Madrid, Madrid, Spain. 11Human Cancer Genetics Program, Spanish National Cancer 
Research Centre, Madrid, Spain. 12Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, 
Spain. 13Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 14Centre for 
Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, 
UK. 15Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 
Germany. 16Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for 
Tumor Diseases (NCT), Heidelberg, Germany. 17German Cancer Consortium (DKTK), German Cancer Research 
Center (DKFZ), Heidelberg, Germany. 18Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
Heidelberg, Germany. 19Research Group Genetic Cancer Epidemiology, University Cancer Center Hamburg (UCCH), 
University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 20Independent contractor, CT(ASCP), MB 
(ASCP), National Cancer Institute, Bethesda, MD, USA. 21Department of Laboratory Medicine and Pathology, Mayo 
Clinic, Rochester, MN, USA. 22Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. 
23Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. 24Centre for Cancer 
Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. 25Cancer Sciences 
Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK. 26Translational Cancer Research 
Area, University of Eastern Finland, Kuopio, Finland. 27Institute of Clinical Medicine, Pathology and Forensic 
Medicine, University of Eastern Finland, Kuopio, Finland. 28Imaging Center, Department of Clinical Pathology, Kuopio 
University Hospital, Kuopio, Finland. 29Department of Pathology, Helsinki University Hospital, University of Helsinki, 
Helsinki, Finland. 30Saarland Cancer Registry, Saarbrücken, Germany. 31Department of Medical Oncology, Family 
Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 32Division of Genetics and Epidemiology, 
The Institute of Cancer Research, London, UK. 33Department of Obstetrics and Gynecology, Helsinki University 
Hospital, University of Helsinki, Helsinki, Finland. 34Department of Health Sciences Research, Mayo Clinic, Rochester, 
MN, USA. 35The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. 
36Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain. 37Division of Breast Cancer 
Research, The Institute of Cancer Research, London, UK. 38Cancer Center, Kuopio University Hospital, Kuopio, 
Finland. 39Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland. 40Department of 
Surgery, Leiden University Medical Center, Leiden, The Netherlands. 41Department of Pathology and Laboratory 
Medicin, Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, University of North 
Carolina, Chapel Hill, NC, USA. 42Department of Clinical Genetics, Leiden University Medical Center, Leiden, The 
Netherlands. 43Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. 44Usher 
Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK. 
45Department of Oncology, Mayo Clinic, Rochester, MN, USA. Hisani N. Horne and Hannah Oh contributed equally to 
this work. Correspondence and requests for materials should be addressed to J.D.F. (email: Jonine.figueroa@ed.ac.uk)
www.nature.com/scientificreports/
3SCIENTIFIC REPORTS |  (2018) 8:6574  | DOI:10.1038/s41598-018-23733-4
Institutional Review Board at each institution, and all subjects provided informed consent or did not opt-out, 
depending on national regulations. All methods were performed in accordance with the relevant guidelines and 
regulations and a list of ethical approval committees are listed at the end of this manuscript.
Risk factor information. The 12 participating studies provided information on one or more of the following 
risk factors for breast cancer: family history of breast cancer in first-degree relatives, reproductive factors includ-
ing age at menarche, parity, age at first full-term birth, oral contraceptive (OC) use among women ≤50 years of 
age, menopausal hormonal use, type of ever menopausal hormone used, and anthropometric measures including 
body mass index (BMI), and height. As a proxy for menopausal status, we used age ≤50 and >50 as a proxy for 
pre- and postmenopausal status respectively, since not all studies captured menopausal status.
E-cadherin tumor tissue measurements. Routinely prepared formalin-fixed paraffin-embedded 
(FFPE) blocks of invasive breast tumors were used to construct TMA blocks at each study center. One-hundred 
and forty-two TMA slides with tumor samples from 6,010 individual patients were prepared for E-cadherin 
staining (ranging from 1–2 cores per patient). TMA’s from all participating studies were stained centrally in 
the Experimental Pathology Laboratory at the National Cancer Institute (NCI) to allow for consistency across 
sites and avoid any potential batch effect that may arise due to systematic variation in staining procedures. We 
recognized the study is unable to control for pre-analytic variables in tissue fixation and processing. However, to 
address this, the Experimental Pathology Lab at NCI carefully re-titrated the IHC assay to provide a stable assay 
across all samples.
IHC staining was performed on a Benchmark ULTRA autostainer (Ventana Medical Systems, Tuscon, 
AZ). TMA sections were deparaffinized with zylene and graded alcohols; antigen retrieval was mediated 
with citrate buffer pH 9 (Dako) for 20 minutes in a pressure cooker. Primary mouse monoclonal antibody, 
anti-E-cadherin (clone NCH-38, 1:500; Dako, Carpinteria, CA) was applied at room temperature for 2 hours. 
The antigen-antibody complex was detected using Envision + (Dako) and DAB was applied for 20 minutes. Slides 
were counterstained with hematoxylin, dehydrated and coverslipped. Slides were imaged with a Hamamatsu 
Nanozoomer (Bridgewater, NJ), at 20× magnification and cataloged using the SlidePath Digital Image Hub (Leica 
Biosystems, Wetzlar, Germany).
As our primary interest was in investigating clinically relevant expression of E-cadherin expression, we used 
the H-scoring system as has been proposed and evaluated in previous publications23–25. Two cytotechnologists 
assessed digital images of TMA spots using the SlidePath Digital Image Hub, blinded to any clinical data. Manual 
readings of each TMA spot recorded the quality of the image (unsatisfactory, limited or satisfactory), percent-
age of cells positively stained for E-cadherin (0, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100%) and the inten-
sity of staining (0 = negative, 1 = weak, 2 = intermediate, and 3 = strong). Reproducibility of IHC scoring was 
assessed based on evaluation of 200 images, by the two cytotechnologist and a pathologist (M.E.S.); inter- and 
intra-observer agreement was excellent (weighted kappa ≥90%; P < 0.001). A summary E-cadherin score was 
calculated using the product of % positive tumor cells and intensity (range of 0–300)23–25. For patients with mul-
tiple spots, the maximum E-cadherin score across the spots was calculated for analysis. The median and inter-
quartile range for the E-cadherin score did not vary substantially across the 12 studies (Supplementary Table 2). 
Tumors having a score of <100 were classified as E-cadherin low and those with a score ≥100 as E-cadherin high. 
Representative images are shown in Supplementary Figure 1. This cut-point was informed by the known relation-
ship between E-cadherin expression and lobular histology supported by evidence in the literature23,32,33. Further 
for sensitivity analysis, we also evaluated a more stringent cut-point defining E-cadherin loss with a score = 0 (i.e. 
no expression of E-cadherin).
Assessment of other tumor markers. Assessment of the tumor markers ER, PR and human epidermal 
growth factor receptor 2 (HER2), and the definition of positive expression of the tumor markers varied across 
studies. For the majority of cases (N = 1891, 32%), ER status were primarily extracted from medical records, 15% 
(N = 908) had ER obtained from IHC staining of whole sections and 28% (N = 1685) had ER obtained from IHC 
staining of TMAs. Previous publications from participating groups in the current study show good concordances 
between marker status from medical records and standardized measurements from TMA analyses34–36.
Statistical analysis. Case-case analyses. As we performed all staining at the NCI to minimize batch effects, 
a pooled analysis was conducted using data from all 12 studies. We performed case-case analyses to assess whether 
there was heterogeneity in risk factor associations by E-cadherin breast tumor expression. We used logistic regres-
sion models to estimate case-case odds ratios (OR) and 95% confidence intervals (CIs) where E-cadherin low vs. 
E-cadherin high expression was the outcome and risk factors the explanatory variables. The ORs were interpreted 
as the risk factor associations of E-cadherin low disease compared to E-cadherin high disease. For each risk factor, 
the category that has been shown to be associated with the lowest overall breast cancer risk in the literature was 
selected as the reference category. Thus, the case-case OR >1 can be interpreted to mean that the risk factor exam-
ined in the analysis is more strongly associated with E-cadherin low tumors than with E-cadherin high tumors 
(ORE-cadherin low vs. control > ORE-cadherin high vs. control). Heterogeneity by E-cadherin subtype were tested using global F 
test37. Because E-cadherin expression may vary by age and study site23,30,31 all models were adjusted for age (in 
10-year categories) and study site. Given that ER status is an important marker of etiologic heterogeneity38, we 
stratified all analyses by ER status (ER+, ER−). Among ER-positive tumors, we also evaluated associations after 
stratification by histology (lobular, ductal/mixed); this was not done among ER-negative tumor due to small num-
bers. To assess the variation in results by study for risk factors that showed evidence of a differential association 
by E-cadherin expression, we fitted study*risk factor interaction terms in the models to estimate p-heterogeneity 
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by study using the likelihood ratio test; P < 0.20 was considered suggestive evidence of between-study heteroge-
neity37. In sensitivity analysis, we also assessed associations with risk factors using a more stringent definition of 
E-cadherin loss, where loss of E-cadherin was defined as those cases with a score of 0.
Survival analysis. For survival analysis, we further excluded patients with distant metastases at diagnosis of the 
primary tumor (N = 63) and those who were missing vital status (N = 174). In total, 5,696 invasive breast cancer 
cases from 12 BCAC studies were included in the survival analysis. A total of 1,085 deaths were observed within 
10 years of diagnosis, 671 due to cancer. We calculated the survival time for each case as the difference between 
the date of diagnosis and the date of death or censoring. Analyses were left censored for time to study entry to 
allow for inclusion of prevalent cases. End of follow-up was defined as the date of death, date of last follow-up or 
10 years, whichever came first. Hazard ratios (HR) and 95% CIs for all-cause mortality and breast cancer-specific 
mortality were estimated using Cox regression models, using study site as a stratifying factor. Multivariable Cox 
models were adjusted for potential confounders: age at diagnosis (in 10-year categories), tumor grade (well/
moderately differentiated, poorly differentiated, or unknown), tumor size (≤2, >2 cm, or unknown), node status 
(positive, negative, or unknown), HER2 status (positive, negative, or unknown), and histology (ductal/mixed, 
lobular, other, or unknown). To assess whether the associations vary by tumor characteristics, we also estimated 
HRs and 95% CI by ER status (positive, negative, unknown), HER2 status (positive, negative, unknown), and, 
among ER-positive tumors, histology (lobular, ductal/mixed, other/unknown).
All statistical tests were two-sided with 5% type-I error. All pooled analyses were performed using the SAS 
software version 9.3 (SAS Institute, Inc, Cary, NC).
Results
Study and tumor characteristics by E-cadherin expression. The median age at breast cancer diag-
nosis was 52 years with some variation by study. E-cadherin low expression by study ranged from 10% to 31% 
(Supplementary Table 2).
Table 1 presents the distribution of clinicopathologic features by level of E-cadherin tumor tissue expression 
(low/high). E-cadherin low tumors were more likely to be lobular, well/moderately differentiated (low grade), 
larger in size (>2 cm), and HER2-negative compared to E-cadherin high tumors (P ≤ 0.005; Table 1). These asso-
ciations were generally consistent across studies (Supplementary Table 3).
Case-case analyses of risk factor associations with E-cadherin tissue expression among 
ER-positive tumors overall and stratified by histology. Table 2 presents risk factor associations 
for ER-positive breast cancers overall and stratified by histology. Among ER-positive cases, compared with 
E-cadherin high tumors E-cadherin low tumors were marginally associated with ever use of menopausal hor-
mones compared with never users (OR = 1.24, 95% CI = 0.97–1.59, P-het = 0.08). No consistent associations 
were observed for E-cadherin status by age at menarche, number of live births, age at live birth, or anthropometric 
measurements (BMI and height; Supplementary Table 4).
Among women with ER-positive tumors, we observed a difference by E-cadherin status for number of live 
births; women who had 1-birth were less likely to have E-cadherin low expression than women with 2 or more 
births (OR = 0.74, 95% CI = 0.58–0.95, Table 2); however no trend was present, based on the result of nulliparous 
women. This relationship was driven by the ductal/mixed tumors while in contrast, for lobular tumors nullipa-
rous women had more frequent loss of E-cadherin compared to those with two or more live births. Other breast 
cancer risk factors examined, family history of breast cancer, age at menarche, age at menopause, age at first birth, 
OC and menopausal hormone use, did not exhibit heterogeneity by E-cadherin expression.
Among ER-positive breast cancers of ductal histology, no breast cancer risk factors examined exhibited het-
erogeneity in their associations by E-cadherin expression (Table 2 and Supplementary Table 4). Analyses using 
a score of 0 to define E-cadherin loss are presented in Supplemental Table 5–6. In these sensitivity analysis, we 
observed a stronger relationship with E-cadherin loss with ER expression (Supplemental Table 5), and analysis 
by risk factors (Supplemental Table 6) showed ever use of menopausal hormones more likely to have E-cadherin 
loss (defined as score = 0) compared to never users among ER-positive tumors (OR = 1.57, 95% CI = 1.06–2.33, 
p = 0.02), other factors did not show significant differences.
Case-case analyses of risk factor associations with E-cadherin tissue expression among 
ER-negative tumors. We did not find differences by E-cadherin expression among ER-negative breast can-
cers (Table 3), although the result for OC use was marginal. Cases that reported ever use of OC’s were more likely 
to be E-cadherin low compared with E-cadherin high tumors (OR = 1.97, 95% CI = 0.96–4.06, P-het = 0.06). No 
significant associations for E-cadherin status were observed for anthropometric measurements including BMI 
and height (Supplementary Table 4). There were too few cases to evaluate with this more stringent cut-point of 0 
to define E-cadherin loss for ER-negative cases.
E-cadherin expression and survival by tumor subtypes. The mean follow-up time was 9.6 years and 
results for all-cause and breast cancer specific survival are presented in Table 4. E-cadherin expression showed no 
significant associations with survival in multivariable models overall, or in any of the tumor subtypes.
Discussion
In our study of nearly 6,000 breast cancer patients, with centrally stained and scored TMA slides, our analyses 
demonstrated E-cadherin loss was significantly associated with lobular histology consistent with previous work. 
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We found limited evidence of heterogeneity of E-cadherin loss, except for menopausal hormone use, to vary by 
risk factors or with 10-year breast cancer specific survival within tumor subtypes.
Analysis by tumor characteristics and E-cadherin loss showed significant associations with lobular histology, 
low grade, larger tumor size and lack of HER2 staining, consistent with previous studies39. Lobular breast cancers 
feature noncohesive cells that are individually dispersed or arranged in a single file pattern, a phenotype that has 
been attributed to dysregulation of cell-cell adhesion, primarily by loss of E-cadherin protein expression40,41. 
Lobular breast cancers because of their single file pattern tend to be harder to detect in screening and hence, are 
larger when diagnosed39, consistent with our data showing E-cadherin loss associated with larger tumor size.
We also observed a relationship between low E-cadherin expression and ever use of menopausal hormones 
among ER-positive tumors, which was more pronounced when we used a more stringent cut-point of E-cadherin 
loss (with a score of 0). Numerous studies have shown that menopausal hormone use, particularly combined 
estrogen-progestin therapy, to be more strongly associated with lobular tumors than with ductal tumors and 
that reduced use of menopausal hormones is associated with a declining incidence rate of lobular cancers at 
the population level11–13,15–17,19–22,42,43. Further, we also observed among ER-negative breast cancers use of OCs 
compared to never users to be almost twice as likely to have E-cadherin loss, although not statistically significant. 
Given that findings suggesting that the relationship between menopausal hormones or OC and breast cancer 
risk are strongly influenced by recent exposure, it is possible that a true association in our data was attenuated by 
our reliance on ever as opposed to current use. Given prior epidemiologic studies and in vitro data showing that 
estrogen may lower E-cadherin expression, the observed relationship with OC or menopausal hormone use may 
be plausible44.
From our analysis of breast cancer risk factors among ER-positive tumors we observed that women who had 
one birth were less frequently E-cadherin low compared to women who had two or more live births. We saw an 
opposite relationship among lobular tumors where nulliparous women had more frequent loss of E-cadherin 
compared to those with two or more live births. Whether E-cadherin loss in tumors is related to reproductive 
characteristics requires larger datasets. With regards to genetic factors, mutation profiling studies targeted at 
CDH1 suggest mutations to be rare and unlikely to explain loss (33/507 based on TCGA data)45,46.
We did not observe associations between E-cadherin and breast cancer specific survival in multivariable 
models as reported in previous studies24–28. Our data, based on the largest analysis of its kind, do not support 
E-cadherin as an important marker of survival in breast cancer patients.
Strengths of our study include the use of large, pooled analysis, centrally stained and scored E-cadherin data 
which allowed for the reduction of any systematic bias that may have been introduced across participating studies. 
Characteristics
Pooled Data Set
E-cadherin low 
(Score < 100)
E-cadherin high 
(Score ≥ 100)
P-value(N = 1191) (N = 4742)
Histology, n (%)
    Ductal 580 (50.9) 3463 (78.4)
    Lobular 410 (36.0) 385 (8.7)
    Mixed 65 (5.7) 251 (5.7)
    Other 84 (7.4) 317 (7.2) <0.0001
Grade, n (%)
    Well/Moderately differentiated 790 (72.2) 2846 (65.2)
    Poorly differentiated 304 (27.8) 1522 (34.8) <0.0001
Tumor size, n (%)
    ≤2 cm 581 (53.9) 2500 (58.7)
    >2 cm 497 (46.1) 1761 (41.3) 0.005
Axillary node involvement, n (%)
    Negative 637 (57.5) 2462 (55.9)
    Positive 471 (42.5) 1944 (44.1) 0.33
ER status, n (%)
    Negative 286 (25.8) 1135 (26.2)
    Positive 822 (74.2) 3206 (73.9) 0.82
PR status, n (%)
    Negative 391 (36.5) 1606 (38.8)
    Positive 679 (63.5) 2533 (61.2) 0.18
HER2 status, n (%)
    Negative 740 (86.3) 2640 (78.0)
    Positive 118 (13.8) 744 (22.0) <0.0001
Table 1. Distribution of select clinicopathologic features among breast cancer cases by E-cadherin tumor tissue 
expression levels in the 12 participating BCAC studies. P-values were estimated using the chi-squared test. 
Abbreviations: E-cad, E-cadherin; ER, estrogen receptor; PR, progesterone receptor.
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Risk Factor
ER-positive Tumors ER-positive Lobular Tumors ER-positive Ductal/Mixed Tumors
No. 
Studies
Cases, N
(E-cadherin 
Low/High)
OR (95% 
CI)a P-hetb
No. 
Studies
Cases, N
(E-cadherin 
Low/High)
OR (95% 
CI)a P-hetb
No. 
Studies
Cases, N
(E-cadherin 
Low/High)
OR (95% 
CI)a P-hetb
Family history of breast 
cancer 10 9 10
Absent 486/1935 1.0 (Ref) 203/179 1.0 (Ref) 232/1497 1.0 (Ref)
Present 236/735 1.18 (0.96–1.46) 0.12 97/79
0.98 
(0.64–1.51) 0.93 121/589
1.19 
(0.89–1.58) 0.24
Age at menarche 10 8 10
≤12 years 171/703 0.95 (0.76–1.20) 76/73
0.85 
(0.55–1.33) 85/566
0.88 
(0.65–1.21)
13 years 155/497 1.14 (0.91–1.44) 74/47
1.45 
(0.91–2.34) 66/406
0.92 
(0.66–1.28)
≥14 years 266/933 1.0 (Ref) 0.33 117/98 1.0 (Ref) 0.11 127/736 1.0 (Ref) 0.72
Parity 10 8 10
  Nulliparous 112/375 0.97 (0.76–1.25) 51/28
1.64 
(0.97–2.77) 47/309
0.81 
(0.57–1.16)
  1 108/510 0.74 (0.58–0.95) 57/52
1.04 
(0.66–1.64) 44/397
0.68 
(0.47–0.98)
  ≥2 399/1377 1.0 (Ref) 0.06 168/156 1.0 (Ref) 0.18 203/1100 1.0 (Ref) 0.09
Age at first birth (among 
parous women) 8 7 8
<20 years 44/137 1.0 (Ref) 15/9 1.0 (Ref) 27/110 1.0 (Ref)
20–24 years 192/718 0.80 (0.54–1.16) 88/85
0.62 
(0.25–1.52) 93/565
0.63 
(0.39–1.03)
25–29 years 150/530 0.79 (0.53–1.17) 66/63
0.56 
(0.22–1.42) 73/421
0.61 
(0.37–1.01)
≥30 years 83/316 0.74 (0.48–1.13) 0.57 39/34
0.64 
(0.24–1.70) 0.68 39/253
0.54 
(0.31–0.95) 0.17
Oral contraceptive 
use (among women at 
age ≤ 50 yearsc)
5 4 5
  Never 49/257 1.0 (Ref) 25/23 1.0 (Ref) 22/207 1.0 (Ref)
  Ever 88/320 1.39 (0.87–2.21) 0.16 32/23
1.00 
(0.37–2.67) 1.00 52/267
1.51 
(0.80–2.84) 0.21
Any menopausal 
hormone (MH) use 
(among women at 
age > 50 yearsc)
7 6 7
Never 192/721 1.0 (Ref) 92/80 1.0 (Ref) 82/564 1.0 (Ref)
Ever 182/568 1.24 (0.97–1.59) 0.08 93/72
1.23 
(0.78–1.94) 0.38 66/429
0.99 
(0.69–1.43) 0.96
Type of ever MH use 
(among women at 
age > 50 yearsc)
7 6 7
Never 192/721 1.0 (Ref) 92/80 1.0 (Ref) 82/564 1.0 (Ref)
Estrogen only 23/66 1.18 (0.68–2.03) 8/13
0.72 
(0.26–2.01) 9/44
0.93 
(0.41–2.11)
Estrogen + Progestin 31/137 1.14 (0.73–1.79) 14/15
0.92 
(0.40–2.08) 14/102
1.36 
(0.70–2.64)
Unknown 128/365 1.29 (0.97–1.72) 0.34 71/44
1.53 
(0.89–2.62) 0.35 43/283
0.91 
(0.59–1.40) 0.76
Table 2. Case-case analyses of established breast cancer risk factors with E-cadherin tumor tissue expression 
(low/high) stratified by tumor histology among estrogen receptor (ER)-positive tumors. aLogistic regression 
analyses were used to estimate the associations between E-cadherin tumor tissue expression and established 
breast cancer risk factors using E-cadherin expression levels (low vs. high) as the outcome variable and the 
risk factors as the independent variable, adjusted for age (10-year categories) and study site. bP-values for 
heterogeneity by E-cadherin subtype were estimated using global F test, adjusted for age and study site. 
cAge ≤ 50 years was used as a proxy for premenopausal status and age >50 years was used as a proxy for 
postmenopausal status. Abbreviations: OR = odds ratio, CI = confidence interval, ER = estrogen receptor Note: 
For each variable, the category that has been shown to be associated with the lowest overall breast cancer risk 
in the literature was selected as the reference category. The case-case OR may be interpreted as the ratio of case-
control ORs for E-cadherin low tumors (vs. controls) and E-cadherin high tumors (vs. controls). The case-case 
OR >1 may suggest that the risk factor association is more strongly associated with E-cadherin low tumors than 
with E-cadherin high tumors (ORE-cadherin low vs. control > ORE-cadherin high vs. control).
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Limitations of this study include limited power for analysis of tumor subgroups due to smaller numbers especially 
for survival analysis. Although staining of E-cadherin was performed centrally, we had lower than expected per-
centages of E-cadherin associated lobular breast cancers, which may reflect variation in calling of histologic sub-
types, but could also indicate the need for molecular profiling methods or more detailed image analysis studies on 
the compartment of where E-cadherin is stained needed, for defining E-cadherin loss47,48. In fact, the percentage 
of E-cadherin low lobular carcinomas varied by study, which could reflect tissue factors that influenced staining, 
variability in classification of cancers as lobular including potential sampling issues if TMA’s did not capture fully 
lobular morphology, or factors related to populations and relative frequency of risk exposures.
In summary, this study provides limited evidence for heterogeneity in risk factor associations or for differ-
ences in survival by E-cadherin tumor tissue expression. Our data are consistent with molecular profiling studies 
showing distinctive expression of genes associated with E-cadherin signaling among ER-positive ductal and lobu-
lar carcinomas10,49. Evaluating genetic susceptibility markers and E-cadherin loss, where data suggest that genetic 
susceptibility factors may influence loss of E-cadherin expression, might provide new insights on pathways of 
E-cadherin loss consistent with histology analysis23,50. Future studies using comprehensive molecular subtyping 
data, including histology, hormone markers and mRNA, might provide new insights on common and distinct 
molecular pathways of E-cadherin loss as well as tumor heterogeneity51.
Risk Factor
Estrogen Receptor Negative Tumors
No. of 
Cases
Cases, N
(E-cadherin Low/High) OR (95% CI)a P-hetb
Family history of breast cancer 9
    Absent 173/660 1.0 (Ref)
    Present 60/207 1.32 (0.88–1.97) 0.18
Age at menarche 8
    ≤12 years 69/225 1.27 (0.87–1.85)
    13 years 43/182 0.94 (0.62–1.44)
    ≥14 years 81/291 1.0 (Ref) 0.34
Parity 9
    Nulliparous 27/108 0.82 (0.51–1.33)
    1 48/190 0.82 (0.56–1.21)
    ≥2 126/441 1.0 (Ref) 0.52
Age at first birth (among parous women) 6
    <20 years 18/59 1.0 (Ref)
    20–24 years 64/257 0.84 (0.46–1.54)
    25–29 years 53/144 1.26 (0.67–2.35)
    ≥30 years 22/86 0.93 (0.45–1.93) 0.32
Oral contraceptive use (among women at age ≤50 yearsc) 5
    Never 23/125 1.0 (Ref)
    Ever 37/132 1.97 (0.96–4.06) 0.06
Menopausal hormone (MH) use (among women at age >50 yearsc) 6
    Never 63/207 1.0 (Ref)
    Ever 48/154 1.25 (0.78–2.00) 0.35
Type of ever MH use (among women at age >50 yearsc) 6
    Never 63/207 1.0 (Ref)
    Estrogen only 4/27 0.46 (0.14–1.45)
    Estrogen + Progestin 14/32 1.67 (0.80–3.49)
    Unknown 30/95 1.38 (0.78–2.46) 0.16
Table 3. Case-case analyses of established breast cancer risk factors with E-cadherin tumor tissue expression 
(low/high) among ER-negative tumors. aLogistic regression analyses were used to estimate the associations 
between E-cadherin tumor tissue expression and established breast cancer risk factors using E-cadherin 
expression levels (low vs. high) as the outcome variable and the risk factors as the independent variable, adjusted 
for age (10-year categories) and study site. bP-values for heterogeneity by E-cadherin subtype were estimated 
using global F test, adjusted for age and study site. cAge ≤ 50 years was used as a proxy for premenopausal 
status and age > 50 years was used as a proxy for postmenopausal status. Abbreviations: OR = odds ratio, 
CI = confidence interval, ER = estrogen receptor Note: For each variable, the category that has been shown to be 
associated with the lowest overall breast cancer risk in the literature was selected as the reference category. The 
case-case OR may be interpreted as the ratio of case-control ORs for E-cadherin low tumors (vs. controls) and 
E-cadherin high tumors (vs. controls). The case-case OR > 1 may suggest that the risk factor association is more 
strongly associated with E-cadherin low tumors than with E-cadherin high tumors (ORE-cadherin low vs. control >  
ORE-cadherin high vs. control).
www.nature.com/scientificreports/
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